Abstracts Archive - Page 2310 of 2425 - ACR Meeting Abstracts

Abstract Number: 1691 • 2012 ACR/ARHP Annual Meeting
Early Signs of Subclinical Inflammation and Local Antibody Production in Early Rheumatoid Lungs
Gudrun Reynisdottir¹, Reza Karimi², Jimmy Ytterberg³, Vijay Joshua¹, Helga Olsen², Aase Haj Hensvold¹, Anders Harju⁴, Johan Grunewald², Sven Nyren⁵, Anders Eklund², Lars Klareskog⁶, Roman Zubarev⁷, Magnus Skold² and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁵Radiology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The aims of the current study was to investigate if inflammatory lung changes are present in RA patients early in the disease process and…
Abstract Number: 1692 • 2012 ACR/ARHP Annual Meeting
Lung Microbiome Differs in Subjects with Rheumatoid Arthritis-Related Autoimmunity without Inflammatory Arthritis Compared to Healthy Seronegative Controls
M. Kristen Demoruelle¹, Jill M. Norris², V. Michael Holers³, Kevin D. Deane¹ and J. Kirk Harris⁴, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Emerging data suggest that microorganisms and mucosal inflammation may play a role in the etiology of rheumatoid arthritis (RA). Furthermore, our published findings…
Abstract Number: 1693 • 2012 ACR/ARHP Annual Meeting
Oncogenic Activation of MAPK in Rheumatoid Arthritis Synovial Fibroblasts
Niloofar L. Farmani¹, Keith K. Colburn², Grace Chan³, Erica Li³, Emil Heinze⁴, Antonia Rubell³, Robert Nishimura⁵ and Richard H. Weisbart³, ¹Medicine, Olive View-UCLA Medical Center, Sylmar, CA, ²Dept Med - Rheum Sect, Loma Linda Univ Medical Center, Loma Linda, CA, ³Research, VAGLAHS, Sepulveda, CA, ⁴Rheumatology, Olive View-UCLA Medical Center, Sylmar, CA, ⁵Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Transformed synovial fibroblasts (SF) mediate joint-specific damage in rheumatoid arthritis (RA) by expressing integrins and metalloproteinase that promote adhesion to and invasion of cartilage.…
Abstract Number: 1694 • 2012 ACR/ARHP Annual Meeting
Infection Risk in Patients with Low Immunoglobulins Following Rituximab Treatment in Rheumatoid Arthritis
Ronald F. van Vollenhoven¹, Gregg J. Silverman², Clifton O. Bingham III³, Patrick Durez⁴, Patrica B. Lehane⁵, Nicola Tyson⁵ and Elena Fisheleva⁵, ¹Karolinska University Hospital, Stockholm, Sweden, ²Medical and Pathology, NYU School of Medicine, New York, NY, ³Department of Medicine, Johns Hopkins University, Baltimore, MD, ⁴University Hospital St Luc, UCL, Brussels, Belgium, ⁵Roche Products Limited, Welwyn Garden City, United Kingdom
Background/Purpose: This study analyzed infection rates in patients (pts) with low immunoglobulin (Ig) serum concentrations following rituximab (RTX) treatment in RA clinical trials. Methods: Pooled…
Abstract Number: 1695 • 2012 ACR/ARHP Annual Meeting
Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data
M. C. Genovese¹, M C. Hochberg², R. B. Cohen³, M. E. Weinblatt⁴, J. Kaine⁵, Edward Keystone⁶, P. Nash⁷, I. Delaet⁸ and R. Alten⁹, ¹Stanford University, Palo Alto, CA, ²Department of Medicine, University of Maryland, Baltimore, MD, ³Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁵Sarasota Arthritis Research Center, Sarasota, FL, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷University of Queensland, Brisbane, Australia, ⁸Bristol-Myers Squibb, Princeton, NJ and Bristol-Myers Squibb, Hopewell, VA, ⁹Schlosspark-Klinik, University Medicine, Berlin, Germany
Background/Purpose: Disease-modifying therapies for RA have proven efficacy, but these drugs may have selective toxicities, such as malignancy, that may increase with duration of treatment.…
Abstract Number: 1696 • 2012 ACR/ARHP Annual Meeting
Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone
Tim Pottel¹, Christoph Schäfer² and Gernot Keyßer², ¹Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06114 Halle (Saale), Germany, ²Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06120 Halle (Saale), Germany
Background/Purpose: The katabolic effects of a systemic treatment with glucocorticoids can lead to a progressive atrophy of the skin. Clinical observation suggests a more pronounced…
Abstract Number: 1657 • 2012 ACR/ARHP Annual Meeting
Peg-IFNa/Ribavirin/Protease Inhibitor Combination Is Highly Effective in HCV-Mixed Cryoglobulinemia Vasculitis
David Saadoun¹, Stanislas Pol², Pascal Lebray Sr.³, François Blanc⁴, Gilles Pialoux⁵, Alexandre Karras⁶, Dorothée Bazin⁷, Emmanuelle Plaisier⁸ and Patrice Cacoub Sr.⁹, ¹DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Hepatology, Cochin Hospital, Paris, France, ³Hepatology, Hôpital Pitié Salpétrière, Paris, France, ⁴hôpital Montpellier, Montpellier, France, ⁵hôpital Tenon, Paris, France, ⁶Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁷Nouvel Hôpital Civil, Strasbourg, France, ⁸Nephrology, Tenon Hospital, Paris, France, ⁹Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France
Background/Purpose: The standard of care treatment of patients presenting a HCV-mixed cryoglobulinemia (MC) vasculitis includes Peg-IFNa plus Ribavirin, w/wo Rituximab. Thirty to 40% of patients…
Abstract Number: 1658 • 2012 ACR/ARHP Annual Meeting
Signal Transducer and Activator of Transcription 3 Induced Synovial Invasion and Migration Is Mediated in Part Through the Notch/Hypoxia-Inducible Factor 1α Pathways
Wei Gao¹, Douglas J. Veale² and Ursula Fearon³, ¹Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ³Dublin Academic Medical Centre, Translation Rheumatology Research Group, Dublin, Ireland
Background/Purpose: To examine the role of Signal Transducer and Activator of Transcription 3 (STAT3) in mediating synovial cell-cell interactions, migration/invasion and key downstream signaling pathways…
Abstract Number: 1659 • 2012 ACR/ARHP Annual Meeting
Ptpome Profile of Rheumatoid Arthritis Fibroblast-Like Synoviocytes: A Novel Role for the Tyrosine Phosphatase SHP-2 As a Modulator of Invasion and Survival
Stephanie Stanford¹, Michael Maestre², Beatrix Bartok³, David L. Boyle⁴, Heather Arnett⁵, Tomas Mustelin⁶, Gary S. Firestein⁷ and Nunzio Bottini², ¹Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ²La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁴Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA, ⁵Amgen, Inc., Seattle, WA, ⁶Sanford-Burnham Institute for Medical Research, La Jolla, CA, ⁷Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Fibroblast-like synoviocytes (FLS) in the synovial intimal lining are key mediators of inflammation and joint destruction in rheumatoid arthritis (RA). These cells assume a…
Abstract Number: 1660 • 2012 ACR/ARHP Annual Meeting
Development of a Bruton’s Tyrosine Kinase (Btk) Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA)
Toshio Yoshizawa, Yuko Ariza, Yoshiko Ueda, Shingo Hotta, Masami Narita and Kazuhito Kawabata, Discovery Research Laboratories 3, Ono Pharmaceutical Co., Ltd., Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is characterized by leukocyte infiltration, synoviocyte hyperplasia and osteoclastogenesis, and tyrosine kinases have key roles in the signaling pathways that regulate…
Abstract Number: 1661 • 2012 ACR/ARHP Annual Meeting
CCR1 Potentiates Gouty Inflammation Following Initial CXCR2-Dependent Neutrophil Recruitment to Sites of Monosodium Urate Crystal Deposition in Mice
Robert P. Friday¹, Terry K. Means², Melissa Tai², Christian D. Sadik² and Andrew D. Luster³, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, MA, ³Massachusetts General Hospital, Charlestown, MA
Background/Purpose: During attacks of acute gouty arthritis, monosodium urate (MSU) crystals elicit a potent neutrophilic inflammatory response in the affected joint, causing exquisite pain and…
Abstract Number: 1662 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Therapy Impairs Intestinal Repair Through Inhibition of Epithelial Proliferation After Injury
Kristine Kuhn¹, Hiroyuki Miyoshi², Nicholas A. Manieri², Nicole P. Malvin², Vinieth Bijanki², Paul Allen² and Thaddeus S. Stappenbeck², ¹Internal Medicine, Washington University School of Medicine, St. Louis, MO, ²Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Inhibition of IL-6 is used for treatment of rheumatoid arthritis and now being investigated as biologic therapy for a wide variety of autoimmune conditions,…
Abstract Number: 1663 • 2012 ACR/ARHP Annual Meeting
G Protein Signaling Modulator 3 Is a Key Regulator of Monocyte-Driven Inflammatory Arthritis
Matthew J. Billard¹, Patrick M. Giguére², Brian Buckley², Marcus W. McGinnis¹, Roman Timoshchenko¹, Peng Liu¹, David P. Siderovski² and Teresa K. Tarrant³, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Medicine/Rheumatology, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Monocytes are critical to rheumatoid arthritis (RA) disease pathogenesis and are recruited to the inflamed synovium by inflammation-driven chemokines. G protein signaling modulator 3…
Abstract Number: 1664 • 2012 ACR/ARHP Annual Meeting
Autoantibodies Are Associated with Subclinical Atherosclerosis and Cardiovascular Endpoints in Caucasian and African American Women in a Prospective Study: the Multi-Ethnic Study of Atherosclerosis (MESA)
Darcy S. Majka¹, Rowland W. Chang², Richard M. Pope³, Marius C. Teodorescu⁴, Elizabeth W. Karlson⁵, Thanh Huyen T. Vu⁶, Joseph Kang⁶ and Kiang Liu⁷, ¹Division of Rheumatology, Northwestern University, Chicago, IL, ²Dept Preventive Med, Northwestern University, Chicago, IL, ³Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ⁴Microbiology, TheraTest Laboratories Inc, Lombard, IL, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Preventive Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁷Preventive Medicine, Northwestern University, Chicago, IL
Background/Purpose: Although the association between rheumatoid arthritis (RA) and cardiovascular disease (CVD) is established, the exact mechanism is not known. Subjects who later develop RA…
Abstract Number: 1665 • 2012 ACR/ARHP Annual Meeting
Associations of Race and Ethnicity with Overall Mortality and Cardiovascular Events Among Patients with End-Stage Renal Disease Due to Lupus Nephritis
Jose A. Gomez-Puerta¹, Sushrut Waikar², Graciela S. Alarcon³, Jun Liu⁴, Daniel H. Solomon⁵, Wolfgang C. Winkelmayer⁶ and Karen H. Costenbader⁷, ¹Section of Clinical Sciences, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ²Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁶Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with SLE and lupus nephritis (LN) are at elevated risks of cardiovascular disease. Past studies have suggested that African American patients with SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].